Main Uses and Therapeutic Intent

Pasmovit is a medication primarily indicated for the management of functional gastrointestinal disorders and conditions involving smooth muscle spasms. It is formulated to address discomfort arising from the digestive tract and the biliary system.

Gastrointestinal Spasms

The medication is used to provide relief from acute or chronic spasms of the stomach and intestines. This includes conditions such as:

• Irritable Bowel Syndrome (IBS): Assisting in the management of abdominal pain and cramping associated with bowel motility issues.
• Functional Gastropathy: Addressing discomfort and irregular contractions in the upper digestive tract.
• Spastic Constipation: Helping to relax the intestinal walls to facilitate more normal movement.

Biliary and Gallbladder Conditions

Pasmovit is also utilized to treat spasms occurring in the biliary tract. This application is relevant for:

• Biliary Colic: Reducing the intense pain caused by temporary obstructions or contractions in the bile ducts.
• Cholecystopathy: Managing symptoms of gallbladder dysfunction where smooth muscle tension contributes to patient discomfort.

Benefits and Clinical Action

The primary benefit of Pasmovit is its antispasmodic effect. Unlike generalized painkillers, it acts specifically on the smooth muscle fibers found in internal organs.

Targeted Relief

By targeting the underlying muscle contraction rather than just masking the pain signal, the medication helps restore a more natural rhythm to the digestive process. This localized action helps reduce the sensation of bloating, pressure, and sharp cramping.

Improvement in Quality of Life

For patients suffering from chronic digestive sensitivities, the stabilization of smooth muscle activity can lead to a reduction in the frequency of painful episodes. This helps in maintaining more consistent gastrointestinal comfort during daily activities and after meals.

Regulatory References

1. Malta Medicines Authority

Official Eligibility and Contraindications

Pasmovit (Phloroglucinol) is authorized for use in specific populations as defined by regulatory prescribing information, which also outlines absolute contraindications and restrictions.

Populations for Whom Use is Prohibited (Contraindicated)

Condition	Affected Population	Severity Classification
Hypersensitivity	Patients with known allergy to the active substance or excipients	Absolute Contraindication
Abdominal Conditions	Patients with functional ileus or known intestinal obstruction	Absolute Contraindication
Metabolic Disorders	Patients with Phenylketonuria (PKU) (for aspartame-containing oral forms)	Absolute Contraindication
Hereditary Sugar Intolerance	Patients with lactose-related hereditary disorders (e.g., Lapp lactase deficiency)	Absolute Contraindication

Age and Conditional Use Restrictions

• Adults are the primary population for use.
• Children over 2 years are approved for use in the symptomatic treatment of spasmodic pain.
• Children under 2 years: Efficacy has not been established, and use is not recommended.
• Pregnancy: Use should only be considered when strictly necessary and must be supervised by a healthcare provider. It is documented for adjuvant use during uterine contractions.
• Lactation (Breastfeeding): Use is not recommended due to a lack of sufficient safety data in this population.

Interactions with other medicines and products

The regulatory profile for Pasmovit (Phloroglucinol) defines specific restrictions based on pharmacodynamic antagonism with certain medicinal products.

---

Documented Pharmacodynamic Interaction

The primary official restriction concerns co-administration with spasmogenic analgesics.

Interaction Type	Interacting Substance	Official Regulatory Restriction
Pharmacodynamic Antagonism	Morphine and Morphine derivatives	Co-administration must be avoided (Prohibited Combination).

This restriction is imposed because major analgesics in the Morphine class possess spasmogenic effects which act against the spasmolytic action of Pasmovit. Co-administration would therefore lead to a counteracting effect, diminishing the intended therapeutic outcome.

---

Absence of Pharmacokinetic and Food Interactions

The official labeling explicitly confirms the absence of certain other common interaction types. No clinically significant pharmacokinetic interactions are documented in regulatory sources; this includes no stated restrictions concerning interactions mediated by CYP enzymes or drug transporters. Additionally, official information states that the absorption of Pasmovit is not affected by food, meaning no separation is required between administration and meals.

Pasmovit, an antiviral co-packaged compound, comprises nirmatrelvir and ritonavir. The primary pharmacodynamic action is executed by nirmatrelvir, a peptidomimetic inhibitor that targets the SARS-CoV-2 main protease (M^pro or 3CLpro). .

---

Nirmatrelvir acts as a covalent inhibitor, selectively binding to the active site of the viral M^pro. This interaction prevents the enzyme from performing its essential function: the proteolytic cleavage of the viral polyprotein precursors (pp1a and pp1ab). The resultant blocked processing step halts the production of functional non-structural proteins necessary for viral assembly and replication.

---

Ritonavir serves as a pharmacokinetic booster with negligible direct antiviral activity. It functions as a mechanism-based inhibitor of the human cytochrome P450 isozyme CYP3A4, the primary enzyme responsible for nirmatrelvir's metabolism. This inhibition decreases the systemic clearance of nirmatrelvir, elevating and prolonging its plasma concentration to maintain inhibitory levels against M^pro. The downstream intracellular consequence is a systemic reduction in the production of functional viral components, leading to an overall system-level modulation characterized by the cessation of active viral replication.

How Pasmovit is Used: Administration and Dosing

The administration of Pasmovit (Phloroglucinol) is centered on symptomatic management. It is primarily utilized as a symptomatic treatment to be taken intermittently, based strictly on the occurrence of the specific condition, rather than on a fixed schedule.

Administration Routes and Forms

Pasmovit is administered via multiple official routes to accommodate varying clinical needs. For rapid intervention in acute episodes, the medicine is approved for intravenous (IV) and intramuscular (IM) injection. For non-acute and follow-up use, the oral route is available, typically as an 80 mg tablet.

Standard Dosing and Frequency

Administration is constrained by strict dose limits and a minimum time interval, ensuring controlled, as-needed usage. The standard single adult oral dose is two tablets (160 mg). Doses may be repeated, but a mandatory minimum interval of two hours must pass between administrations. The total intake for an adult must not exceed a maximum of six tablets (480 mg) within a 24-hour period.

Preparation and Age-Specific Use

Administration preparation varies by the user's age. For adults, the tablets may be taken orally or dissolved under the tongue without water for rapid effect. For children over two years, the tablets must be dissolved in a glass of water before administration. Specific dose maximums are also stipulated for the pediatric population over two years, restricting their total daily intake to a maximum of two tablets (160 mg) per 24 hours.

Administration Constraints

The labeled instructions include a specific procedural constraint: the use of Pasmovit is restricted with major analgesics, such as morphine or its derivatives, as they can cause smooth muscle spasms that may antagonize the antispasmodic action of Phloroglucinol.

Research evidence / Overview of Studies for Pasmovit

This section provides a summary of the clinical research conducted on Pasmovit (Phloroglucinol). It describes what types of studies have been performed, what outcomes were monitored, and what aspects of the evidence remain limited or unclear, without giving any clinical advice.

---

Evidence for Acute Visceral Pain (Colic)

Research has explored its use in conditions associated with acute or disruptive episodes, such as painful spasms linked to renal (kidney) or biliary (gallbladder) colic. Research includes Phase 3 randomized comparative studies, where the drug was observed in patients experiencing acute pain. These studies examined outcomes describing episodic or acute changes, such as the time elapsed before initial measured pain scores changed and the measured frequency of spasms.

In those comparative studies, the research described patterns where the measured outcomes for Pasmovit were similar to the measured outcomes of the reference drugs used. However, findings were mixed when Pasmovit was studied as an add-on treatment alongside common analgesics. One randomized, double-blind, placebo-controlled trial specifically examined the acute symptoms during renal colic and found no evidence that adding Pasmovit to the standard analgesic regimen was associated with a change in pain relief measured at the 1-hour primary endpoint compared to the analgesic alone.

---

Evidence for Functional Digestive Spasms

The drug was evaluated in short-term studies focusing on conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS). These include randomized, double-blind, placebo-controlled trials that were studied for patients with the diarrhea-dominant subtype (IBS-D). Studies focused on patient-reported outcomes describing perceived discomfort and functional measures.

One key finding described patterns where a statistically higher proportion of patients met the predefined criteria for overall response (a global assessment outcome) compared to the placebo group over a three-week period. However, the same research indicates that measured outcomes for individual symptoms, such as abdominal pain, discomfort, or stool consistency, were not statistically distinguishable from those reported by the placebo group.

---

Evidence for Obstetrical Support

Pasmovit was studied for use in the specific context of obstetrical support during labor. Research primarily consists of systematic reviews and meta-analyses that aggregate data from multiple randomized trials. The aggregated data from these trials described measured outcomes related to the duration of labor. This research describes patterns primarily observed when the drug was associated with other treatments used during labor, such as oxytocin.

---

What Remains Unclear in the Research

The research provides limited insight into the drug's applicability for managing chronic, ongoing pain or general gynecological discomfort. The research base often focused on specific adult populations and follow-up durations were limited, meaning there is limited information for long-term outcomes or how outcomes related to physical discomfort evolved outside of the short-term intervals monitored in the existing trials.

Key Studies & References Summary of Product Characteristics (SPC) for Phloroglucinol Dihydrate (e.g., Malta Medicines Authority document detailing indications)

Common questions about Pasmovit (FAQ)

Q: What is Pasmovit used for?

A: Pasmovit is indicated for the management of chronic, non-specific skeletal muscle tension. It is used as an adjunctive measure alongside rest and physical therapy.

Q: How does Pasmovit work in the body?

A: Pasmovit is thought to affect the central nervous system to potentially reduce muscle tone, but the precise mechanism of action remains an area of study.

Q: What are the common side effects of Pasmovit?

A: Common reported side effects may include drowsiness, dizziness, and mild dry mouth. It is important to discuss any concerns with a healthcare professional.

Q: Can I take Pasmovit with other medications?

A: Before taking Pasmovit, it is important to inform your healthcare provider of all current medications, including over-the-counter products and supplements, as interactions are possible.

The official storage and disposal requirements for Pasmovit (Phloroglucinol) ensure product stability and environmental safety, as mandated by regulatory documents.

Official Storage Conditions

Requirement	Stated Condition
Temperature	Store below 30 C (Do not store above 30 C).
Protection	Protect from light and moisture.
Packaging	Store in the original outer carton.
Child Safety	Keep out of the sight and reach of children.

The injectable solution, once the ampoule is opened, must be used immediately as its stability is compromised thereafter. The product must not be used after the expiration date printed on the packaging.

Official Disposal Rules

Unused or expired Pasmovit must not be disposed of via household waste or wastewater. Discarding the medicine must be done in accordance with local regulatory requirements for pharmaceutical waste to prevent environmental contamination.